OPCH · Option Care Health

The thesis

Option Care Health's shares are pinned to a $32.05-per-share cash takeover by Clayton, Dubilier & Rice (CD&R) and McKesson, so they are more likely to lag than lead the S&P 500 over the next three months. Two dated events decide whether the deal stays on track: the federal antitrust waiting period, which expires on 3 December 2026 unless extended, and the stockholder vote on 15 December 2026.

The price already reflects a deal the market expects to close. The shares closed at $31.70 on 11 November 2026, just under the cash price, and have stayed between $31.50 and $31.70 at every close from 4 November to 11 November 2026.

The third-quarter report on 4 November 2026 lowered the risk that the buyers try to reprice. Net revenue rose 4.1% to $1,493.5 million and adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) rose 4.3% to $124.6 million. Both growth rates are faster than in the second quarter. The definitive proxy, dated 9 November 2026, set the meeting date and confirmed that both sides filed for antitrust clearance on 3 November 2026.

Bullish and bearish views on Option Care Health, Inc.

The bull case on Option Care Health, Inc. (OPCH), in brief: the business improved after signing. The bear case: upside is capped at $32.05.

Bull case

• The business improved after signing. Third-quarter net revenue grew 4.1% to $1,493.5 million and adjusted diluted earnings per share (EPS) rose 8.9% to $0.49, the company reported on 4 November 2026. Second-quarter revenue had grown only 1.9%, so a weak quarter is no longer a reason for the buyers to reopen the price.
• The debt is moving toward market. The definitive proxy cites an amended debt commitment letter dated 30 October 2026 covering up to $3.15 billion in loans and a $500 million revolving credit facility. Bloomberg reported on 5 November 2026 that Goldman Sachs, Bank of America and Barclays were leading a roughly $3.1 billion debt sale for the deal, including leveraged loans and secured and unsecured bonds.
• The buyers pay more if they walk. The proxy sets a parent termination fee of $291,927,951, twice the company's $145,963,976 fee. Equity commitments from CD&R Fund XII and McKesson total up to $2,873,295,853.
• The timeline is fixed. Both sides filed Hart-Scott-Rodino (HSR) antitrust notifications on 3 November 2026 and asked for early termination, according to the 9 November 2026 definitive proxy. The special meeting is set for 15 December 2026, with a record date of 3 November 2026.

Bear case

• Upside is capped at $32.05. The shares closed at $31.70 on 11 November 2026. A fixed cash payout leaves almost no room to rise, so a rising S&P 500 leaves them behind.
• A rival bid is unlikely. The preliminary proxy dated 28 October 2026 says the buyers refused a go-shop clause, which would have let the company seek other offers after signing. The final agreement has a no-shop clause with a fiduciary out, and a higher offer would also have to cover the $145,963,976 company termination fee.
• More regulators than antitrust alone. Closing also requires state healthcare transaction notice reviews, state pharmacy licensure approvals and consents from certain state health regulators, according to the definitive proxy. The outside date of 5 October 2027 leaves room for a long review.
• No guidance and no call. The company withdrew its financial guidance after signing and released third-quarter results on 4 November 2026 without a conference call. Operating detail between now and closing will be thin.

Price setup

The shares closed at $31.70 on 11 November 2026, up 31.7% from $24.07 on 13 August 2026 in adjusted daily closes. Nearly all of that gain came on the 6 October 2026 deal announcement. The 52-week closing low was $19.52 on 15 May 2026.

The 50-day moving average stood at $27.78 and the 200-day at $26.15 on 11 November 2026. Both still carry the pre-deal prices. A close back toward the 50-day average would mean the market sees real risk to the deal.

The 52-week intraday high was $36.80 on 23 January 2026, and the last close sits 13.9% below it. Only a higher offer could carry the shares back to that range. Above the 50-day average and below the cash price, the shares track the time left to closing and the odds of clearance.

Catalysts ahead

• 3 December 2026: Scheduled expiry of the Hart-Scott-Rodino antitrust waiting period, unless terminated early or extended by a second request. A clean expiry removes the federal antitrust hurdle. A second request from the FTC or DOJ would push closing out and widen the gap to $32.05.
• 15 December 2026: Virtual special meeting of stockholders to vote on the merger. Approval by a majority of outstanding shares leaves only state healthcare and pharmacy-licensure approvals before closing.
• ~30 June 2027 (est.): Expected deal closing, guided to the first half of 2027; outside date 5 October 2027. Closing pays out $32.05 in cash. Slippage toward the outside date would point to friction in state reviews.

What would change the view

A daily close above $36.59, the highest close of the past year (22 January 2026), which would signal a bid above $32.05 and show the shares leading the S&P 500; a disclosed competing proposal above $32.05 would also prove the call wrong.

What it trades with

While the deal is pending, the shares follow the deal's odds more than their health-services peers. Earnings and sector moves at Teladoc (TDOC), AMN Healthcare (AMN), ICON (ICLR) and IQVIA (IQV) should move Option Care Health little. Credit markets matter more, because the roughly $3.1 billion debt sale Bloomberg reported on 5 November 2026 funds most of the purchase. So does any regulatory news on McKesson (MCK), the strategic buyer. In a falling S&P 500 the pinned price would hold up better than the index; in a rising one it lags.